Cover Image
市場調查報告書

PharmaPoint:精神分裂症 - 現在/未來的主要企業

Schizophrenia - Current and Future Players

出版商 GlobalData 商品編碼 299716
出版日期 內容資訊 英文 114 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:精神分裂症 - 現在/未來的主要企業 Schizophrenia - Current and Future Players
出版日期: 2016年11月01日 內容資訊: 英文 114 Pages
簡介

本報告提供急速成長的精神分裂症治療藥市場相關資料研究,以包含新加入廠商的競爭情形為焦點,再加上主要企業相關最新資訊詳細的分析,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 市場預測

  • 全球市場
    • 預測
    • 推動因素·障礙

第4章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Janssen Pharmaceuticals
    • Eli Lilly and Company
    • Roche
    • Alkermes
    • EnVivo Pharmaceuticals

第5章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC1067FPR

GlobalData has released its pharma report, "Schizophrenia - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Schizophrenia Market. The report identifies and analyses the key companies shaping and driving the global Schizophrenia market. The report provides insight into the competitive Schizophrenia landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Schizophrenia
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Schizophrenia sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Schizophrenia market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Schizophrenia market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Catalyst 6
  • 2.2 Related Reports 7

3 Market Outlook 8

  • 3.1 Global Markets 8
    • 3.1.1 Forecast 8
    • 3.1.2 Drivers and Barriers - Global Issues 12

4 Current and Future Players 13

  • 4.1 Overview 13
  • 4.2 Trends in Corporate Strategy 16
  • 4.3 Company Profiles 18
    • 4.3.1 Alkermes 18
    • 4.3.2 Dainippon Sumitomo 20
    • 4.3.3 Eli Lilly 23
    • 4.3.4 Intra-Cellular Therapies 25
    • 4.3.5 Janssen 27
    • 4.3.6 Lundbeck 30
    • 4.3.7 Minerva Neurosciences 33
    • 4.3.8 Otsuka 35

5 Appendix 39

  • 5.1 Bibliography 39
  • 5.2 Abbreviations 81
  • 5.3 Methodology 87
  • 5.4 Forecasting Methodology 87
    • 5.4.1 Diagnosed Schizophrenia Patients 87
    • 5.4.2 Percent Drug-Treated Patients 88
    • 5.4.3 Launch and Patent Expiry Dates 88
    • 5.4.4 General Pricing Assumptions 89
    • 5.4.5 Individual Drug Assumptions 90
    • 5.4.6 Generic Erosion 105
    • 5.4.7 Pricing of Pipeline Agents 105
  • 5.5 Primary Research - KOLs Interviewed for this Report 107
  • 5.6 Primary Research - Prescriber Survey 109
  • 5.7 About the Authors 110
    • 5.7.1 Analyst 110
    • 5.7.2 Therapy Area Director 111
    • 5.7.3 Epidemiologist 111
    • 5.7.4 Managing Epidemiologist 111
    • 5.7.5 Global Director of Therapy Analysis and Epidemiology 112
  • 5.8 About GlobalData 113
  • 5.9 Disclaimer 113

List of Tables

  • Table 1: Schizophrenia Market - Drivers and Barriers, 2015-2025 12
  • Table 2: Key Companies in the Schizophrenia Market in the 7MM, 2015 14
  • Table 3: Alkermes' Schizophrenia Portfolio Assessment, 2015 19
  • Table 4: Alkermes SWOT Analysis in Schizophrenia, 2015-2025 20
  • Table 5: Dainippon Sumitomo's Schizophrenia Portfolio Assessment, 2015 22
  • Table 6: Dainippon Sumitomo SWOT Analysis in Schizophrenia, 2015-2025 23
  • Table 7: Eli Lilly's Schizophrenia Portfolio Assessment, 2015 24
  • Table 8: Eli Lilly SWOT Analysis in Schizophrenia, 2015-2025 25
  • Table 9: Intra-Cellular Therapies' Schizophrenia Portfolio Assessment, 2015 26
  • Table 10: Intra-Cellular Therapies SWOT Analysis in Schizophrenia, 2015-2025 27
  • Table 11: Janssen's Schizophrenia Portfolio Assessment, 2015 29
  • Table 12: Janssen SWOT Analysis in Schizophrenia, 2015-2025 30
  • Table 13: Lundbeck's Schizophrenia Portfolio Assessment, 2015 32
  • Table 14: Lundbeck SWOT Analysis in Schizophrenia, 2015-2025 33
  • Table 15: Minerva Neurosciences' Schizophrenia Portfolio Assessment, 2015 34
  • Table 16: Minerva Neurosciences SWOT Analysis in Schizophrenia, 2015-2025 35
  • Table 17: Otsuka's Schizophrenia Portfolio Assessment, 2015 37
  • Table 18: Otsuka SWOT Analysis in Schizophrenia, 2015-2025 38
  • Table 19: Key Launch Dates 88
  • Table 20: Key Patent/Exclusivity Expiries 89
  • Table 21: High-Prescribing Psychiatrists (Non-KOLs) Surveyed, By Country 109

List of Figures

  • Figure 1: Global Sales for Schizophrenia by Region, 2015-2025 10
  • Figure 2: Global Sales for Schizophrenia by Drug Class, 2015-2025 11
  • Figure 3: Global Sales of Products for Schizophrenia by Company, 2015-2025 15
  • Figure 4: Company Portfolio Gap Analysis in Schizophrenia, 2015-2025 16
Back to Top